title: Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial.
abstract: OBJECTIVE
  To compare the efficacy of multidose medroxyprogesterone acetate and a multidose monophasic combined oral contraceptive (OC) for hemodynamically stable women with nongestational, acute uterine bleeding.
  
  
  METHODS
  Hemodynamically stable patients with acute uterine bleeding sufficient to justify immediate medical or surgical intervention were enrolled in an open-label, randomized trial comparing oral medroxyprogesterone acetate 20 mg and a monophasic combination OC containing 1 mg norethindrone and 35 mug of ethinyl estradiol, each administered three times per day. Doses were reduced after 1 week to 20 mg per day and one tablet per day for the next 3 weeks for the medroxyprogesterone acetate and OC groups, respectively. Following baseline assessment, patients completed daily treatment and symptom logs collected at 14 and 28 days after initiation of therapy.
  
  
  RESULTS
  Forty patients were randomly assigned, 20 in each group; 33 were evaluated at the 14-day visit. Emergency surgical procedures were avoided in 100% of those women taking medroxyprogesterone acetate and 95% of the OC group. Cessation of bleeding had occurred in 88% of the OC group and 76% of those receiving medroxyprogesterone acetate, with a median time to bleeding cessation of 3 days for both groups. Compliance with therapy was higher in the medroxyprogesterone acetate group than the OC group, but there was no overall difference in the incidence of treatment-related nausea and bloating.
  
  
  CONCLUSIONS
  This randomized trial is limited by sample size but suggests that both regimens may be effective and reasonably well tolerated.
  
  
  BACKGROUND
  Current Clinical Trials (clinicaltrials.gov, www.clinicaltrials.gov) Identifier: NCT00350480
  
  
  METHODS
  II-1.
authors.affiliation: Department of Obstetrics, Kaiser Permanente Southern California Los Angeles Medical Center, Los Angeles, Los Angeles, California, USA. M.G.Munro@kp.org
authors.forename: Malcolm G
authors.initials: MG
authors.lastname: Munro
authors.forename: Nakia
authors.initials: N
authors.lastname: Mainor
authors.forename: Romie
authors.initials: R
authors.lastname: Basu
authors.forename: Mikael
authors.initials: M
authors.lastname: Brisinger
authors.forename: Lorena
authors.initials: L
authors.lastname: Barreda
mesh_terms: D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D017060:Patient Satisfaction; D018579:Patient Selection; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000601:surgery
chemical_list: D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D017258:Medroxyprogesterone Acetate